Skip to main content

Table 3 Patient characteristics

From: Characteristics of ambulatory anticoagulant adverse drug events: a descriptive study

Characteristic Total events
(n = 169)
ADEs
(n = 88)
Potential ADEs
(n = 81)
Age, mean +/- SD 68.1 +/- 13.2
(range 36-95)
69.5 +/- 13.5
(range 37-90)
66.6 +/- 12.8
(range 36-95)
Insurance, No. (%)    
   Private 32 (18.9%) 19 (21.6%) 13 (16.0%)
   Private/Medicare 100 (59.2%) 52 (59.1%) 48 (59.3%)
   Private/Medicaid 3 (1.8%) 0 3 (3.7%)
   Medicare 12 (7.1%) 7 (8.0%) 5 (6.2%)
   Medicare/Medicaid 14 (8.3%) 7 (8.0%) 7 (8.6%)
   Medicaid 8 (4.7%) 3 (3.4%) 5 (6.2%)
Indication, No. (%)    
   Atrial fibrillation 92 (54.4%) 51 41
   Deep vein thrombosis 46 (27.2%) 19 27
   Pulmonary embolism 26 (15.4%) 13 13
   Stroke 23 (13.6%) 15 8
   Valve replacement 23 (13.6%) 11 12
   Hypercoagulable 11 (6.5%) 3 8
   Other 10 (5.9%) 4 6
   Indeterminate 1 (0.6%) 0 1
   None 1 (0.6%) 1 0
Duration of warfarin therapy, No. (%)    
   <1 mo 25 (14.8) 12 (13.6) 13 (16.0)
   1-3 mos 17 (10.1) 8 (9.1) 9 (11.1)
   4-6 mos 9 (5.3) 3 (3.4) 6 (7.4)
   7-12 mos 11 (6.5) 8 (9.1) 3 (3.7)
   1-5 y 29 (17.2) 13 (14.8) 16 (19.8)
   > 5 y 25 (14.8) 15 (17.0) 10 (12.3)
   Indeterminate 52 (30.8) 28 (31.8) 24 (29.6)
   No prescribed warfarin 1 (0.6) 1 (1.1) 0
Seen at Duke clinic or hospital within 30 d, No. (%)* 115 (73.2%) 52 (65.0%) 63 (81.8%)
Anticoag. therapy addressed within 30 d, No. (%)* 90 (57.3%) 43 (53.8%) 47 (61.0%)
  1. *Denominator limited to events with a prior encounter note present in the EHR:
  2. Total events = 157, ADEs = 80, pADE = 77.